Waukegan High student tests positive for tuberculosis
A student at the Brookside campus of Waukegan High School was diagnosed with an active case of tuberculosis (TB) last week while the Waukegan Community Unit School District 60 community was on spring break.
The student is currently isolated from others and undergoing treatment, according to an email from the Lake County Health Department, which notified the district and they are working together to protect the community.
District 60 Superintendent Theresa Plascencia said in an email to the school community Friday that students and staff identified as having close contact with the individual were already notified by email and given recommended actions to take.
'As a precaution, the school is undergoing recommended cleaning procedures,' Plasencia said. 'School operations will continue as usual, with continued cleaning and COVID-era air filtration enhancements in place.'
TB is a disease spread through the air from person to person by an individual with active — not latent — TB, according to the health department. Symptoms of the disease include coughing, night sweats and weight loss.
'While TB is contagious, it is not spread as easily as other illnesses, such as cold or flu,' the health department said in the email. 'Although TB can be serious, it is a treatable disease. Not everyone infected with TB becomes sick.'
Working closely with the health department, Plascencia said people can transmit the disease through speaking, singing or coughing. People with active TB are, 'most likely to spread TB germs to people they spend time with every day.'
In her email to the school community, Plascencia said that conditions like a persistent cough lasting three weeks or longer, coughing up blood, pain with breathing, chest pain, fatigue, weakness, loss of appetite, fever, chills or night sweats are warning signs. A person with those symptoms should get tested.
'Treatment of latent TB can prevent active TB from developing which is why testing when exposed is important,' the health department said. 'We encourage anyone who is contacted by the health department about an exposure to take the necessary steps to get tested.'
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Los Angeles Times
an hour ago
- Los Angeles Times
Anaheim Regional Medical Center nurses' union wins pay boost, security upgrades
Registered nurses who work at the Anaheim Regional Medical Center voted to ratify their first-ever labor contract with the hospital on Wednesday night, an agreement they claim will improve patient care. As negotiations carried on, safety remained a top priority for nurses represented by SEIU Local 121RN. The union in April held an info picket outside of the hospital to draw attention to such issues. In the past, nurses and their aides have screened people for weapons and drugs at the hospital's emergency room entrance. While nurses did not gain the walk-through metal detectors they pushed for in bargaining, the hospital has agreed to staff security guards with metal detector wands at different entry points within six months to a year. Security staff will also take over bag searches and provide identification for visitors. 'That's something we're not responsible for anymore,' said Liza Lorenzo, a telemetry nurse who has worked at the hospital for the past 15 years. 'We have more time to do bedside care, as opposed to going through people's belongings, which was not safe for us, as well.' When reached, a spokesperson for AHMC Healthcare, the company that owns the hospital, declined to comment on the contract. The security changes come before Assembly Bill 2975, which the union advocated for and requires hospitals throughout the state to have weapons detection screening policies by March 2027. Nurses also won a minimum 19% pay raise over the four years of the contract. The salary boost comes with additional measures to ensure there are four nurses for every patient at a specialty unit, a ratio mandated by state law. For telemetry units, the nurse-patient ratio is five-to-one. During the pandemic, Lorenzo claimed that the hospital stretched its nurse-to-patient ratios beyond their limits but nurses now have protections in place to hold management accountable. 'We made sure that we have a resource nurse for every five nurses or more,' said Lorenzo, who helped negotiate the contract. 'If there's five nurses in the unit, we will have a resource nurse dedicated for that unit alone. Obviously, better staffing leads to faster response, reduces medical errors and prevents staff burnout.' Nurses are hopeful that the boosted salaries and ratio protections will go a long way toward addressing what they called inadequate staffing at the hospital. The union also proposed forming a pandemic task force following the experience of the COVID-19 pandemic that overwhelmed hospitals in Orange County. The contract guarantees that nurses will have enough personal protective equipment for three months while following U.S. Center for Disease Control and Prevention guidelines. 'We're more prepared in the case of another pandemic, as opposed to just scrambling,' Lorenzo said. As nurses also complained about broken-down MRI machines and the lack of running hot water at times, the hospital has also pledged to make timely repairs to medical equipment while addressing other maintenance issues. Lorenzo beamed with pride when speaking about critical provisions of the newly ratified contract, which arrived in less than one year's time since safety concerns first prompted nurses to unionize in August. 'Our efforts have paid off,' she said. 'Now we have our first contract. This is not only for us, but also for our patients and the community.'
Indianapolis Star
3 hours ago
- Indianapolis Star
Moderna Announces Update on Investigational Pandemic Influenza Program
Phase 1/2 H5 avian flu vaccine study shows positive interim results Company has been notified that HHS will terminate Moderna's award for late-stage development of pre-pandemic influenza vaccines CAMBRIDGE, MA / ACCESS Newswire Moderna, Inc. (NASDAQ:MRNA) today announced positive interim data from a Phase 1/2 clinical study (NCT05972174) evaluating the safety and immunogenicity of its investigational pandemic influenza vaccine, mRNA-1018, in approximately 300 healthy adults aged 18 years and older. The interim results focus on a vaccine candidate targeting the H5 avian influenza virus subtype. The Company had previously expected to advance the program to late-stage development with the U.S. Department of Health and Human Services (HHS); however, today Moderna received notice that HHS will terminate the award for the late-stage development and right to purchase pre-pandemic influenza vaccines. 'While the termination of funding from HHS adds uncertainty, we are pleased by the robust immune response and safety profile observed in this interim analysis of the Phase 1/2 study of our H5 avian flu vaccine and we will explore alternative paths forward for the program,' said Stéphane Bancel, Chief Executive Officer of Moderna. 'These clinical data in pandemic influenza underscore the critical role mRNA technology has played as a countermeasure to emerging health threats.' The Phase 1/2 study evaluated a two-dose regimen of Moderna's investigational avian influenza vaccine. mRNA-1018 demonstrated a rapid, potent and durable immune response. At baseline, pre-existing immunity was minimal, with only 2.1% of participants showing hemagglutination inhibition (HAI) antibody titers ≥1:40, an HAI titer considered to correlate with protection. At Day 43, three weeks after the second vaccination, 97.8% of participants achieved titers ≥1:40 with a 44.5-fold increase of titers from baseline. The investigational vaccine was generally well-tolerated, with no dose-limiting tolerability concerns observed. Most solicited adverse reactions were Grade 1 or 2 and did not increase significantly with number of doses or between first and second doses. Further data is expected to be submitted for presentation at an upcoming scientific meeting. Moderna will explore alternatives for late-stage development and manufacturing of the H5 program consistent with the Company's strategic commitment to pandemic preparedness. About Moderna Moderna is a leader in the creation of the field of mRNA medicine. Through the advancement of mRNA technology, Moderna is reimagining how medicines are made and transforming how we treat and prevent disease for everyone. By working at the intersection of science, technology and health for more than a decade, the company has developed medicines at unprecedented speed and efficiency, including one of the earliest and most effective COVID-19 vaccines. Moderna's mRNA platform has enabled the development of therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases and autoimmune diseases. With a unique culture and a global team driven by the Moderna values and mindsets to responsibly change the future of human health, Moderna strives to deliver the greatest possible impact to people through mRNA medicines. For more information about Moderna, please visit and connect with us on X (formerly Twitter), Facebook, Instagram, YouTube and LinkedIn. Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including statements regarding: the clinical development of mRNA-1018, the safety and immunogenicity data from the Phase 1/2 study; the cancellation of the development contract for Moderna's pandemic flu program by the U.S. Department of Health and Human Services; and the exploration of alternative paths for development of the vaccine program. The forward-looking statements in this press release are neither promises nor guarantees, and you should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties, and other factors, many of which are beyond Moderna's control and which could cause actual results to differ materially from those expressed or implied by these forward-looking statements. These risks, uncertainties, and other factors include, among others, those risks and uncertainties described under the heading 'Risk Factors' in Moderna's Annual Report on Form 10-K for the fiscal year ended December 31, 2024, and in subsequent filings made by Moderna with the U.S. Securities and Exchange Commission, which are available on the SEC's website at Except as required by law, Moderna disclaims any intention or responsibility for updating or revising any forward-looking statements contained in this press release in the event of new information, future developments or otherwise. These forward-looking statements are based on Moderna's current expectations and speak only as of the date of this press release. Moderna Contacts Investors: Lavina Talukdar Senior Vice President & Head of Investor Relations +1 617-209-5834 SOURCE: Moderna, Inc. View the original press release on ACCESS Newswire
Yahoo
3 hours ago
- Yahoo
How AI could help stop the next pandemic before it starts
Could artificial intelligence tools be used to stop the next pandemic before it starts? During the Covid pandemic, new technology developed by researchers at Johns Hopkins and Duke universities didn't exist. But, for the first time, researchers there say they've devised a revolutionary large language modeling tool - the type of generative AI used in ChatGP - to help predict the spread of any infectious disease, such as bird flu, monkeypox, and RSV. That could help save lives and reduce infections. 'Covid-19 elucidated the challenge of predicting disease spread due to the interplay of complex factors that were constantly changing,' Johns Hopkins' Lauren Gardner, a modeling expert who created the Covid dashboard that was relied upon by people worldwide during the pandemic, said in a statement. 'When conditions were stable the models were fine. However, when new variants emerged or policies changed, we were terrible at predicting the outcomes because we didn't have the modeling capabilities to include critical types of information,' she added. 'The new tool fills this gap.' Gardner was one of the authors of the study published Thursday in the Nature Computational Science journal. The tool, named PandemicLLM, considers recent infection spikes, new variants, and stringent protective measures. The researchers utilized data that had never been used before in pandemic prediction tools, finding that PandemicLLM could accurately predict disease patterns and hospitalization trends one to three weeks out. The data included rates of cases hospitalizations and vaccines, types of government policies, characteristics of disease variants and their prevalence, and state-level demographics. The model incorporates these elements to predict how they will come together and affect how disease behaves. They retroactively applied PandemicLLM to the Covid pandemic, looking at each state over the course of 19 months. The authors said the tool was particularly successful when the outbreak was in flux. It also outperformed existing state-of-the-art forecasting methods, including the highest performing ones on the Centers for Disease Control and Prevention's CovidHub. 'Traditionally we use the past to predict the future,' author Hao 'Frank' Yang, a Johns Hopkins assistant professor of civil and systems engineering, said. 'But that doesn't give the model sufficient information to understand and predict what's happening. Instead, this framework uses new types of real-time information.' Going forward, they are looking at how large language models can replicate the ways individuals make decisions about their health. They hope that such a model would help officials to design safer and more effective policies. More than a million Americans have died from Covid. It's not a matter of if there will be a next pandemic, but when. Right now, the U.S. is dealing with the spread of H5N1 bird flu, RSV, HMPV, pertussis, and measles, among other health concerns. Vaccination rates for measles have plunged since the pandemic, and general vaccine hesitancy has increased. That has resulted in fears that the nation could see decades of health progress reversed. Furthermore, U.S. health officials have acted to separate from global efforts to respond to pandemics, withdrawing from the World Health Organization earlier this year. Last month, they limited access to Covid vaccines for certain groups. 'We know from Covid-19 that we need better tools so that we can inform more effective policies,' Gardner said. 'There will be another pandemic, and these types of frameworks will be crucial for supporting public health response.'
